QMS Medical Allied Services Ltd (QMSMEDI) — shareholding pattern, promoter holding, financials and share price
About QMS Medical Allied Services Ltd (QMSMEDI)
QMS Medical Allied Services Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as QMSMEDI and on the BSE under scrip code 535483. Its ISIN is INE0FMW01018.
Incorporated in 2017, QMS Medical Allied Services Ltd is a manufacturer and distributor of medical devices [1]
QMS Medical Allied Services is an integrated healthcare company that markets, distributes and services medical devices and runs Patient Support Programs (PSP), B2B health camps and an e-commerce platform, combining product distribution including Q-Devices with technology-enabled patient journey services across India.
Financially, the company delivered 9MFY26 revenue of Rs 128.5 crore, up 15% YoY, with EBITDA of Rs 20.1 crore and PAT of Rs 9.9 crore; however Q3FY26 showed sequential moderation with revenue of Rs 37.3 crore and PAT of Rs 3.2 crore, highlighting short-term volatility amid sustained nine‑month growth.
Listed peers in Medical Equipment & Supplies: Yash Optics & Lens Ltd, Aprameya Engineering Ltd, Nureca Ltd, Earkart Limited, Avience Biomedicals Ltd, Choksi Asia Ltd.
Valuation & Returns
10 Jul 2026At ₹106.16 a share on 10 Jul 2026, QMS Medical Allied Services Ltd (QMSMEDI) was valued at a price-to-earnings ratio of 17.22x against an industry P/E of 44.11x and a price-to-book of 2.29x on a book value of ₹46.39 per share as of Mar 2025. Solomo computes return on equity of 13.29% and return on capital employed of 15.32% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 17.22x
- Industry P/E
- 44.11x
- P/B
- 2.29x
- EPS (TTM)
- ₹6.16
- Book value / share
- ₹46.39
- ROE
- 13.29%
- ROCE
- 15.32%
- ROA
- 6.28%
- Debt / equity
- 0.67x
- Dividend yield
- 0.47%
- EBITDA margin
- 15.58%
- 52-week range
- ₹68.95 – ₹114
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, QMS Medical Allied Services Ltd (QMSMEDI) reported revenue of ₹173 crore, net profit of ₹12 crore and earnings per share of ₹5.24. That compares with revenue of ₹156 crore and net profit of ₹14 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹44.42 crore and net profit ₹2.02 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 122 | 156 | 173 |
| Net profit (₹ cr) | 9 | 14 | 12 |
| EPS (₹) | 4.66 | 6.26 | 5.24 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 14.77% | -0.33% | 27.74% |
| Profit growth | 10.51% | -0.84% | 52.22% |
| Stock price CAGR | - | -8% | 32% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.11% of QMS Medical Allied Services Ltd (QMSMEDI) (unchanged from the previous quarter). Market capitalisation was ₹205 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2022.
Largest disclosed public shareholders in Jun 2026: GAURANG SHASHIKANT VASANI 3.29%, STELLAR ASSET MANAGEMENT FUND - AMRIT KAAL OPPORTUNITIES FUND 1.59%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.11% | - | - | - | - |
| Mar 2026 | 68.11% | - | - | - | - |
| Sep 2025 | 68.11% | - | - | - | - |
| Jun 2025 | 73.67% | - | - | - | - |
| Mar 2025 | 73.67% | - | - | - | - |
| Sep 2024 | 73.67% | - | - | - | - |
| Mar 2024 | 73.67% | - | - | - | - |
| Sep 2023 | 73.67% | - | - | - | - |